AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Commercial Metals Company
Video analysis: CMC
All videosNo video analysis for this stock yet. Request one from our team.
News: CMC
Can Commercial Metals Sustain Its Strong Core EBITDA Growth Momentum?
CMC's core EBITDA surges y/y in the first nine months of fiscal 2026, aided by acquisitions, margin expansion and TAG Program benefits.
Here's Why Commercial Metals (CMC) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here's Why Commercial Metals (CMC) is a Strong Momentum Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Celularity and MuseCell Innovations® Announce U.S. Manufacturing Collaboration for the Dezawa MuseCell® Platform
[url="]Celularity Inc.[/url] (Nasdaq: CELU) (âCelularityâ), a longevity-focused regenerative and cellular medicine company, and [url="]MuseCell InnovationsÂ
CMC Named to Newsweek's America's Greatest Companies 2026 List
IRVING, Texas, Aug. 27, 2026 /PRNewswire/ -- CMC (NYSE: CMC) today announced that it has been named to Newsweek's America's Greatest Companies 2026 list. The annual ranking, developed by Newsweek in partnership with Plant-A Insights Group, recognizes 650 U.S. companies based on financial leadership, innovation, performance as an employer and sustainability.
Commercial Metals Company: Working On Its Foundation
Commercial Metals Company is executing a strategy focused on higher-margin, less capital-intensive operations following $2.5 billion in transformative M&A. Commercial Metals targets $1.65–$1.80 billion core EBITDA and $11B revenue by 2029, aiming to nearly double free cash flow per share. Leverage remains in the low 2s as Commercial Metals prioritizes EBITDA growth and shareholder returns via increased buybacks over rapid debt reduction.
AN2 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business and Scientific Highlights
AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics
Neurogene Reports Second Quarter 2026 Financial Results and Highlights Recent Updates
Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological
Similar companies
-
Gerdau S.A.
GGB
·
New York Stock Exchange
Compare
-
Ternium S.A.
TX
·
New York Stock Exchange
Compare
-
Cleveland-Cliffs Inc.
CLF
·
New York Stock Exchange
Compare
-
Element Solutions Inc
ESI
·
New York Stock Exchange
Compare
-
OR Royalties Inc.
OR
·
New York Stock Exchange
Compare
-
Eagle Materials Inc.
EXP
·
New York Stock Exchange
Compare